Search Results for "Hydromorphone"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Hydromorphone. Results 11 to 14 of 14 total matches.
Fentanyl Buccal Tablet (Fentora) for Breakthrough Pain
The Medical Letter on Drugs and Therapeutics • Sep 24, 2007 (Issue 1270)
, 400, 10-15 min 12.32-36.47
(Cephalon) 600, 800 mcg
buccal tabs
Hydromorphone
Dilaudid 2, 4, 8 mg ...
The FDA has approved a transmucosal tablet formulation of fentanyl citrate (Fentora - Cephalon) for management of breakthrough pain in opioid-tolerant patients with cancer. An oral transmucosal fentanyl lozenge on a stick (Actiq, and others) is also available for this indication, and is widely used off-label for chronic, non-cancer pain as well.
Oxycodone OxyContin
The Medical Letter on Drugs and Therapeutics • Sep 17, 2001 (Issue 1113)
-release
hydromorphone q12h (Hydromorph Contin − available in Canada) (P Mussi-LoRusso et al, Eur
J Pain ...
Recent reports of inappropriate use and diversion of OxyContin tablets have prompted Purdue Pharma to include a "Black Box Warning"in the product labeling to call attention to the potential for abuse and to reinforce the FDA-approved indication "...for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time..."
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
in a fixed-dose combination with acetaminophen 31.20
31.20
Hydromorphone – generic
Dilaudid (Rhodes ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Tapentadol (Nucynta) - A New Analgesic
The Medical Letter on Drugs and Therapeutics • Aug 10, 2009 (Issue 1318)
concern.
Tapentadol has a high potential for abuse (similar to that
of hydromorphone). Discontinuing ...
The FDA has approved tapentadol hydrochloride (Nucynta - Ortho-McNeil Janssen) for oral treatment of moderate to severe acute pain in patients ≥18 years old. It has been classified as a Schedule II controlled substance